Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

9-Norbornyl-6-chloropurine is a novel antileukemic compound interacting with cellular GSH

P. Placková, N. Rozumová, H. Hrebabecky, M. Sála, R. Nencka, T. Elbert, A. Dvoráková, I. Votruba, H. Mertlíková-Kaiserová,

. 2013 ; 33 (8) : 3163-8.

Language English Country Greece

Document type Journal Article, Research Support, Non-U.S. Gov't

AIM: 6-Chloropurines substituted at position 9 with bicyclic skeletons represent promising chemotherapeutic agents. We explored the metabolism and membrane transport of 9-norbornyl-6-chloropurine (NCP) aiming to understand its mechanism of action. MATERIALS AND METHODS: The metabolism of NCP was studied in vitro in whole cells (CCRF-CEM), cellular extracts, subcellular fractions and purified enzymes. Transport experiments were conducted in Caco-2 cell monolayers. RESULTS: Three metabolites were identified, a glutathione conjugate (NCP-GS), NCP-cysteinylglycine and NCP-cysteine. Both glutathione-S-transferase inhibition and glutathione (GSH) depletion prevented metabolite formation and increased the cytotoxicity of NCP. Transepithelial transport (Caco-2) indicated good permeability, with Papp (12.6±0.3) ×10(-5) cm/s. Importantly, the drug induced glutathione depletion in treated cells and affected the activity of several GSH-dependent enzymes. CONCLUSION: The novel nucleoside analog NCP represents a promising orally available antileukemic agent, acting through lowering of GSH levels in tumor cells.

000      
00000naa a2200000 a 4500
001      
bmc14040650
003      
CZ-PrNML
005      
20140108102432.0
007      
ta
008      
140107s2013 gr f 000 0|eng||
009      
AR
035    __
$a (PubMed)23898074
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Placková, Pavla
245    10
$a 9-Norbornyl-6-chloropurine is a novel antileukemic compound interacting with cellular GSH / $c P. Placková, N. Rozumová, H. Hrebabecky, M. Sála, R. Nencka, T. Elbert, A. Dvoráková, I. Votruba, H. Mertlíková-Kaiserová,
520    9_
$a AIM: 6-Chloropurines substituted at position 9 with bicyclic skeletons represent promising chemotherapeutic agents. We explored the metabolism and membrane transport of 9-norbornyl-6-chloropurine (NCP) aiming to understand its mechanism of action. MATERIALS AND METHODS: The metabolism of NCP was studied in vitro in whole cells (CCRF-CEM), cellular extracts, subcellular fractions and purified enzymes. Transport experiments were conducted in Caco-2 cell monolayers. RESULTS: Three metabolites were identified, a glutathione conjugate (NCP-GS), NCP-cysteinylglycine and NCP-cysteine. Both glutathione-S-transferase inhibition and glutathione (GSH) depletion prevented metabolite formation and increased the cytotoxicity of NCP. Transepithelial transport (Caco-2) indicated good permeability, with Papp (12.6±0.3) ×10(-5) cm/s. Importantly, the drug induced glutathione depletion in treated cells and affected the activity of several GSH-dependent enzymes. CONCLUSION: The novel nucleoside analog NCP represents a promising orally available antileukemic agent, acting through lowering of GSH levels in tumor cells.
650    _2
$a protinádorové látky $x chemie $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a biologický transport $x účinky léků $7 D001692
650    _2
$a Caco-2 buňky $7 D018938
650    _2
$a vysokoúčinná kapalinová chromatografie $7 D002851
650    _2
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a epitelové buňky $x účinky léků $x metabolismus $7 D004847
650    _2
$a glutathion $x metabolismus $7 D005978
650    _2
$a glutathiontransferasa $x antagonisté a inhibitory $x metabolismus $7 D005982
650    _2
$a lidé $7 D006801
650    _2
$a leukemie $x farmakoterapie $x patologie $7 D007938
650    _2
$a puriny $x chemie $x farmakologie $x terapeutické užití $7 D011687
650    _2
$a xanthinoxidasa $x antagonisté a inhibitory $x metabolismus $7 D014969
650    _2
$a inhibitory cytochromu P450 $7 D065607
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rozumová, Nela $u -
700    1_
$a Hrebabecky, Hubert $u -
700    1_
$a Sála, Michal $u -
700    1_
$a Nencka, Radim $u -
700    1_
$a Elbert, Tomás $u -
700    1_
$a Dvoráková, Alexandra $u -
700    1_
$a Votruba, Ivan $u -
700    1_
$a Mertlíková-Kaiserová, Helena $u -
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 33, č. 8 (2013), s. 3163-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23898074 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140107 $b ABA008
991    __
$a 20140108103132 $b ABA008
999    __
$a ok $b bmc $g 1005046 $s 839162
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 33 $c 8 $d 3163-8 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20140107

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...